首页> 外文期刊>Frontiers in Physics >Integration of fluorescence differential path-length spectroscopy to photodynamic therapy of the head and neck tumors is useful in monitoring clinical outcome
【24h】

Integration of fluorescence differential path-length spectroscopy to photodynamic therapy of the head and neck tumors is useful in monitoring clinical outcome

机译:将荧光微分路径长度光谱法整合到头颈部肿瘤的光动力疗法中,可用于监测临床结果

获取原文
           

摘要

The use of fluorescence differential pathlength spectroscopy (FDPS) has the potential to provide real-time information on photosensitiser pharmacokinetics, vascular physiology and photosensitizer photobleaching based dosimetry of tumors in the oral cavity receiving m-tetrahydroxyphenylchlorin (mTHPC) photodynamic therapy (PDT). Reflectance spectra can be used provide quantitative values of oxygen saturation, blood volume fraction, blood vessel diameter, and to determine the local optical properties that can be used to correct raw fluorescence for tissue absorption. Patients and methods: Twenty-seven lesions in the oral cavity, either dysplasias or cancer were interrogated using FDPS, before and immediately after the therapeutic illumination. The average tumor center to normal mucosa ratio of fluorescence was 1.50 ± 0.66. mTHPC photobleaching was observed in 24 of the lesions treated. The average extent of photobleaching was 81% ± 17%. Information from FDPS spectroscopy coupled with the clinical results of the treatment identified 3 types of correctable errors in the application of mTHPC-PDT: Two patients exhibited very low concentrations of photosensitizer in tumour center, indicating an ineffective i.v. injection of photosensitiser or an erroneous systemic distribution of mTHPC. In one in tumor we observed no photobleaching accompanied by a high blood volume fraction in the illuminated tissue, suggesting that the presence of blood prevented therapeutic light reaching the target tissue. All 3 of the these lesions had no clinical response to PDT. In four patients we observed less than 50% photobleaching at the tumor margins , suggesting a possible geographic miss. One patient in this group had a recurrence within 2 months after PDT even though the initial response was good. The integration of FDPS to clinical PDT yields data on tissue physiology, photosensitiser content and photobleaching that can help identify treatment errors that can potentially be corrected.
机译:荧光差分光程谱(FDPS)的使用有可能提供基于光敏剂药代动力学,血管生理学和基于光敏剂光漂白的口腔中接受间四羟基苯氯(mTHPC)光动力疗法(PDT)的肿瘤剂量的实时信息。可以使用反射光谱来提供氧饱和度,血液体积分数,血管直径的定量值,并确定可用于校正组织吸收的原始荧光的局部光学性质。患者和方法:在治疗性照明之前和之后,使用FDPS对口腔中的27个病变(发育异常或癌症)进行了检查。肿瘤中心与正常粘膜的平均荧光比为1.50±0.66。在所治疗的24个病灶中观察到mTHPC光漂白。光漂白的平均程度为81%±17%。来自FDPS光谱学的信息以及该治疗的临床结果确定了mTHPC-PDT应用中的3种可纠正的错误类型:两名患者在肿瘤中心的光敏剂浓度非常低,表明静脉内注射无效。注射光敏剂或mTHPC的全身分布错误。在一个肿瘤患者中,我们在被照亮的组织中未观察到光漂白并伴有高血容量分数,这表明血液的存在阻止了治疗光到达目标组织。这些病变中的所有3个对PDT无临床反应。在四名患者中,我们在肿瘤边缘观察到不到50%的光致漂白,表明可能存在地理缺失。即使初始反应良好,该组中的一名患者在PDT后2个月内复发。 FDPS与临床PDT的集成产生了有关组织生理,光敏剂含量和光漂白的数据,这些数据可以帮助识别可以纠正的治疗错误。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号